Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
- 8 January 2002
- journal article
- Vol. 166 (1), 44-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Pharmaceutical Price Controls and Patient WelfareAnnals of Internal Medicine, 2001
- The Heartbreak of Drug PricingAnnals of Internal Medicine, 2001
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- Recommendations of the Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- The Role of Cost-effectiveness Analysis in Health and MedicineJAMA, 1996
- A study of the quality of life and cost-utility of renal transplantationKidney International, 1996
- Guidelines for Economic Analysis of Pharmaceutical ProductsPharmacoEconomics, 1993
- Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.1993
- How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.1992